Case Report

Neurocognitive assessments and long-term outcome in an adult with 2-methyl-3-hydroxybutryl-CoA dehydrogenase deficiency

Karolina M. Stepien⁎, Philomena McCarthya, Eileen P. Treacya,b, James J. O’Byrnea, Gregory M. Pastoresa,b

a National Centre for Inherited Metabolic Diseases, The Mater Misericordiae University Hospital, Dublin, Ireland
b University College Dublin, Ireland

ABSTRACT

Background: 2-Methyl-3-hydroxybutryl-CoA dehydrogenase deficiency (MHBDD) is a rare X-linked disorder associated with the accumulation of 2-methyl-3-hydroxybutyric acid in body fluids due to abnormal activity of MHBDD which is involved in isoleucine degradation [1]. Degradation of the branched-chain amino acid isoleucine in humans takes place in mitochondria via the concerted action of a series of enzymes, during which isoleucine first undergoes transamination to 2-keto-3-methylbutyrate, followed by oxidative decarboxylation to 2-methylbutyryl-CoA [2].

Almost 30 patients with MHBDD have been reported worldwide. To date, seven pathogenic variants in HADH2 have been reported to result in MHBDD. Among missense pathogenic variants, p.Arg130Cys is the most common [2–5].

The classical infantile form of MHBDD disease is characterized by a progressive neurodegenerative course with retinopathy and cardiomyopathy, leading to death at the age of 2–4 years or later [6]. Clinical presentation, however, can be very heterogeneous [7], ranging from diarrhea, vomiting, lethargy, disturbance of consciousness, dyspnea and metabolic acidosis during acute illness, to slow neurocognitive decline in adulthood [5, 8]. Some patients may present with developmental delay or neurologic problems without regression and patients without neurologic regression during youth may develop neurologic problems and/or other symptoms later in life. Indeed Lorea et al. (2015) reported a patient who had a HADH2 p.Ala158Val variant and developed Parkinsonism at the age of 27 years [9].

Most patients with MHBDD described so far presented in childhood; in a few cases diagnosis was not established until adulthood [9, 10]. This paper presents the long-term neurocognitive outcomes in an adult patient affected with MHBDD.

Results: This paper outlines the long-term neurocognitive outcomes in a 38-year old man with MHBDD. Several psychometric tests were used to assess his cognitive ability and adaptive functioning in childhood during an acute illness and in adulthood when the patient showed deterioration in the ability to walk or speak.

Conclusions: There is an increasing demand for an accurate and objective measure of cognitive functioning that can be used to follow the natural progression of MHBDD. Psychological assessment may enable the identification of organic problems. The application and interpretation of psychometric tests used in children may vary from those used in adults.

1. Background

2-Methyl-3-hydroxybutryl-CoA dehydrogenase deficiency (MHBDD) is a rare X-linked disorder associated with the accumulation of 2-methyl-3-hydroxybutyric acid in body fluids due to abnormal activity of MHBDD which is involved in isoleucine degradation [1]. Degradation of the branched-chain amino acid isoleucine in humans takes place in mitochondria via the concerted action of a series of enzymes, during which isoleucine first undergoes transamination to 2-keto-3-methylbutyrate, followed by oxidative decarboxylation to 2-methylbutyryl-CoA [2].

https://doi.org/10.1016/j.ymgmr.2018.06.005
Received 21 April 2018; Received in revised form 16 June 2018; Accepted 16 June 2018
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
deleterious pathogenic variant, c.745G > C (p.Glu249Gln). His mother was an asymptomatic carrier.

At the age of 38, he presented to the Adult Metabolic Clinic with significant speech and motor impairment. He displayed a passive behaviour, and although he was unable to verbally communicate, he smiled when engaged. The clinical course of his mild condition and his steady neurocognitive impairment are presented in Fig. 1.

On examination he exhibited tremor and signs of dystonia treated with carbidopa and levodopa (Sinemet 62.5 mg daily). He had marked contractures in his knee and ankle joints and was unable to walk independently. He had marked muscle atrophy (sarcopenia), attributed to lack of mobility and chronic wheelchair use and intake of a low protein diet (0.7 g/kg) since childhood. Audiometry showed he had normal ipsilateral acoustic reflexes indicating healthy VIIIth nerve pathways and hearing was assessed as not worse than mild loss.

His biochemical tests showed plasma ammonia, renal function and liver function tests within normal reference ranges. Plasma amino acids showed leucine 121 μmol/L (38–83), isoleucine 64 μmol/L (77–162) and valine 205 μmol/L (151–302). Acylcarnitine profile was normal and free carnitine was 16.6 μmol/L. His most recent urine organic acids profile showed a mild increased excretion of 2-methyl-3-hydroxybutyrate, a moderate increase in excretion of tiglylglycine with no 2-methylacetoacetate detected. A slight increase in vanillactate and vanilpyruvate acids detected were likely to be secondary to carbidopa and levodopa intake prescribed for tremor and dystonia.

Table 1 outlines psychology assessments that were performed at different stages of his life.

The patient completed the Wechsler Intelligence Scale for Children (WISC) at 7 and 16 years of age and the Wechsler Adult Intelligence Scale (WAIS) at age 20 years. His scores on these tests were reported to be within the mild, moderate and mild range respectively. At 7 years, there was statistically significant discrepancy between his Performance Intelligence Quotient (IQ) (mild range) and his Verbal IQ (low average range). The patient completed the Stanford Binet at 10 years indicating an IQ within the Moderate range.

It was not possible to re-administer the WAIS at 38 years due to the patient's limited receptive capacity and significantly limited motor and verbal skills. Information was gathered from clinical interview with his mother, and his adaptive functioning was assessed using the Adaptive Behaviour Assessment System-Third Edition (ABAS-3). The patient's general Adaptive Composite Score on the ABAS-3 was reported to be in the extremely low range (< 0.1 percentile). This score is consistent with a moderate IQ in the absence of a comprehensive IQ assessment. His reading was assessed at 16 and 20 years using the Schonell Reading Test, and his level when retested remained stable between 7 and 8 years. His social functioning as assessed on the Vineland Adaptive Intelligence Scale.
| Psychometric test | Used in child/adult | Outcomes measured | Validated for assessment in diseases | References |
|-------------------|---------------------|-------------------|-------------------------------------|------------|
| Adaptive Behaviour Assessment System-3 (ABAS-3) | Used with children and adult populations (0–89 years) | Assessment of adaptive skills needed to independently care for oneself, respond to others and meet the demands at home, school work and in the community. | Norm referenced based on US data | Harrison & Oakland [25] |
| Goodenough Draw-a-Person Test | Children 2–13 years | A nonverbal measure of intelligence. | Normative data unknown to author | Goodenough-Harris [26] |
| Schonell Reading Test | Children and adults | Reading ability | A nonverbal measure of intelligence | Thorndike et al. [27] |
| Stanford-Binet Intelligence Scale fourth Edition | Children and adults from 2 to 85 years | - Intelligence (IQ) - Fluid reasoning - Knowledge - Quantitative reasoning - Visual-spatial processing - Working memory | Normed on a representative sample of 4800 individuals, children/adults | |
| Vineland Adaptive Behaviour Scales | 0–90 years | Measures personal and social skills from birth through to adulthood | | Sparrow et al. [28] |
| Wechsler Intelligence Scale for Children-revised (WISC-R) | 6–16 years | - Intelligence - Verbal Comprehension Index - Visual Spatial Index - Fluid Reasoning Index - Working Memory Index - Processing Speed Index | - Adults with intellectual disabilities in residential care/non-residential facilities (ambulatory/non-ambulatory) - Children with hearing and vision impairment - UK and US norms including - Intellectually gifted children - Children with mild or moderate intellectual disability - Children with specific learning disorders (reading, written expression and math) - Children with ADHD/disruptive behavior - Children who are English Language Learners - Children with autism spectrum disorder with language impairment - Children with autism spectrum disorder without language impairment - Children with traumatic brain injuries - Not normed on metabolic population but valid for those with mild/moderate intellectual disability | Wechsler [29] |
| Wechsler Adult Intelligence Scale | 16–90 years (+ 11 months) | | | Wechsler [30] |
Behaviour Scale was between 7 and 8 years. This domain was assessed on the ABAS-3 and was 3 standard deviations (SD) below the mean (0.2 percentile). It was reported that from the age of 26 he was fully dependent on carers for daily living skills such as dressing, toileting, and feeding. Reportedly around the same time, the patient began to display challenging and aggressive behaviour.

3. Discussion

The natural history of MHBDD disease is not clear in view of a small number of cases described. There are distinct differences in the phenotype of the condition with sensory, cognitive, and behavioural manifestations varying considerably [7]. This case, probably the longest living patient with this rare disease, illustrates the challenges associated with and importance of a regular psychology review to assess cognitive function in a patient with an Inherited Metabolic Disease (IMD).

There is a paucity of data on the long-term outcomes in patients with IMDs and no clear guidelines or consensus on what battery of psychological tests to use in such cases. The Wechsler Intelligence Scales are the gold standard in IQ tests and are not normed on a population of patients with IMD. Monitoring IQ and adaptive functioning in patients with IMD at various time points using appropriate tests may facilitate tracking disease progression and inform care planning, educational/occupational opportunities, interventions and the efficacy of different therapy options.

This patient had several tests performed throughout his life (Fig. 1 and Table 1). Various tests were administered in this case, aimed at assessing different cognitive functions to detect the magnitude of changes, if any, over time (Table 1). The review of his previous assessments revealed that deterioration occurred in the patient’s verbal and fine and gross motor skills. In retrospect, it was difficult to determine which tests were best to monitor the patient’s cognitive and adaptive function due to the limited findings reported. However, it appears that all tests administered (see Table 1) were helpful at the time in guiding educational/occupational placements and identifying the need for further neurological investigation.

Assessments of IQ were performed using the standardized Wechsler Intelligence Scales. Variations in IQ test results may reflect changes in assessment measures used or differences in administration from one examiner to the next [11]. However, correlations on the Wechsler Scales between current and earlier versions may detect subtle changes [11, 12]. In this patient, assessments were performed by different psychologists over the period of observation, and different subtests were administered which may have impacted on the overall score.

It may be important to consider certain tests that are appropriate for the patient and can be used throughout the lifespan. If tests are to be used longitudinally (e.g., Wechsler Intelligence Scales and Stanford Binet), accurate reporting of results will allow for tracking of IQ throughout the lifespan. Several publications have reported on the use of Wechsler Intelligence Scales in patients with an IMD. Whilst neuropsychologic research into the cognitive development of patients with an IMD has been limited to standardized intelligence tests, achievement tests and adaptive behaviour scales [13–15] are not always suitable. Long-term follow-up of neuropsychological functioning in patients with metabolic disorders remains difficult due to limited opportunities for comprehensive neuropsychological evaluations [16]. Identifying tests that can be administered to those who have significantly limited verbal and motor skills may be relevant in some patients with IMD. For instance, the Test of Nonverbal Intelligence fourth Edition (TONI-4) for those age 6–89 years (+11 months) assesses non-verbal intelligence requiring minimal physical response.

3.1. Cognitive assessment during the acute illness

Psychological assessment may call attention to the presence of organic problems, and may help clinicians identify changes in executive function and facilitate early intervention. Early identification and initiation of appropriate treatment may prevent or delay developmental and spasticity problems [17]. Emerging concerns should prompt further specific executive function testing [18].

In our case all psychology assessments were performed at the time of acute illness such as whooping cough/measles, or when learning difficulties were evident and proved to be useful in identifying sudden deterioration in cognitive function or a change in disease course. Specific recommendations were made following early assessment (e.g., appropriate school placement).

3.2. Dementia and cognition

Degradation of the branched-chain amino acid isoleucine in humans takes place in the mitochondria via the concerted action of a series of enzymes, including MHBDD [2]. It has been speculated that multifunctional enzymes might play a role in the pathogenesis of Alzheimer’s disease [2, 19]. Cognitive assessments are difficult to administer and interpret, when undertaken in individuals with moderate to profound intellectual disability, as they rely on verbal communication, particularly receptive communication [20]. Moreover, respondents often need to use fine motor skills such as writing and drawing, and many individuals with moderate to severe intellectual disability have poor hand dexterity [20, 21]. In addition, most assessments lack sensitivity in terms of differentiating levels of lower intellectual functioning [20], or responses cannot be scored properly [20, 22].

3.3. Treatment and neurocognitive assessment

Treatment applied before brain damage occurs generally results in better cognitive outcomes [23]. The efficacy of the applied low protein diet used for MHBDD in the context of neurocognitive function has never been fully evaluated, although it was shown to reduce the number of episodes of acute decompensation [24]. Our patient remained on a low protein diet throughout his life. Despite having a steady and gradual decline in his neurocognitive status, he has never experienced any acute decompensation in his life.

4. Conclusions

There is an increasing demand for measures of cognitive function that are able to accurately and objectively track the natural progression of IMDs. Psychological assessment may enable the identification of organic problems. A psychologist is an important member of a multidisciplinary team in metabolic medicine to be able to carry out assessment when required and to use this information to support the patient’s management. Further work is required to validate the psychometric tests on a larger group of adult patients with rare disease.

Consent for publication

The patient’s family gave their full informed consent.

Ethical approval and consent to participate

N/A

Availability supporting data

N/A

Competing interests

KMS, PM, EPT, JOB, GMP have no conflict of interest for this publication.
All authors would like to thank The Metabolic Laboratory at Temple Street Hospital for their ongoing support in monitoring biochemical parameters in patients with Inherited Metabolic Diseases.

References

[1] J. Zschocke, J.P. Ruiter, J. Brand, et al., Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched chain fatty acid and isoleucine metabolism, Pediatr. Res. 48 (2000) 852–855.

[2] R. Ofman, J.P. Ruiter, M. Feenstra, et al., 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency is caused by mutations in the HADH2 gene, Am. J. Hum. Genet. 72 (2003) 1300–1307.

[3] C. Perez Cerda, J. Garcia-Villoria, R. Ofman, P.R. Sala, B. Merinero, et al., 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBH) deficiency: a X-linked inborn error of isoleucine metabolism that may mimic mitochondrial disease, Pediatr. Res. 58 (2005) 488–491.

[4] J. García-Villoria, A. Navarro-Sastre, C. Fons, C. Pérez-Cerdá, A. Baldellou, Study of patients and carriers with 2-methyl-3-Hydroxybutyryl-CoA dehydrogenase (MHBH) deficiency: difficulties in the diagnosis, Clin. Biochem. 42 (2009) 27–33.

[5] K. Rauschenberger, K. Scholer, J.O. Saa, et al., A non-enzymatic function of 17beta-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival, EMBO Mol. Med. 2 (2010) 51–62.

[6] J. Zschocke, HSD10 disease: clinical consequences of mutations in the HSD17B10 gene, J. Inherit Met. Dis. 35 (2012) 81–89.

[7] R. Ensenauer, H. Neiderhoff, J.P.N. Ruiter, R.J.A. Wanders, Clinical variability in 3-hydroxy-2-methylbutyryl-CoA dehydrogenase deficiency, Ann. Neurol. 52 (5) (2002) 656–659.

[8] J.O. Saa, R. Forstner, W. Sperli, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: impaired catalbism of isoleucine presenting as neurodegenerative disease, Brain and Development 26 (2004) 12–14.

[9] C.F. Lorea, A. Sitta, B. Yamamoto, et al., Case report: atypical juvenile parkinsonism and basal ganglia calcifications due to HSD10 disease, J. Inherit. Metab. Dis. 38 (Suppl. 1) (2015) 210.

[10] S.E. Olpin, R.J. Pollitt, J. Mcmenamin, et al., 2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency in a 23-year-old man, J Inherit Met. Dis. 25 (2002) 477–482.

[11] M.H. Beaucamp, V. Anderson, A. Boneh, Cognitive and social profiles in two patients with Cobalamin C disease, J. Inherit. Metab. Dis. 32 (Suppl. 1) (2009) S27–S33.

[12] D.H. Salkowske, L.R. Goruchs, L.G. Weiss, J. Zsu, C.A. Patterson, General ability index for the WAIS-III: Canadian norms, Can. J. Behav. Sci. 37 (1) (2005) 44–48.

[13] M. Biermaa, A. Jakubowska-Winecka, A. Tyllis-Zymanska, The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase, Pediatric Endocr. Diab. Metab. 16 (4) (2010) 249–254.

[14] J. Davison, S. Kearney, J. Horton, K. Foster, A.C. Peet, C.J. Hendrikz, Intellectual and neurological functioning in Morquio syndrome (MPS IVa), J. Inherit. Metab. Dis. 36 (2) (2012) 323–328.

[15] E. Shapiro, K. Bjoraker, E. Guler, K. Delaney, L. Charnas, J. Tolar, et al., Neuropsychological outcomes in Hurler syndrome: 7–20 years post-hematopoietic stem cell transplantation, Mol. Genet. Metab. 96 (2) (2009) S40–S41.

[16] S.E. Waaslben, J. He, R. Mccarter, Assessing psychological functioning in metabolic disorders: validation of the adaptive behavior assessment system, second edition (ABAS-II), and the behavior rating inventory of executive function (BRIEF) for identification of individuals at risk, J. Inherit Metab. Dis. Rep. 21 (2015) 35–43.

[17] R.L. Edwards, K. Moseley, Y. Watanabe, L.J. Wong, J. Ottina, S. Yano, Long-term neurodevelopmental effects of early detection and treatment in a 6-year-old patient with argininaemia diagnosed by newborn screening, J. Inherit. Metab. Dis. 32 (Suppl. 1) (2009) S197–S200.

[18] J. Bouchereau, J. Leduc-Leballeur, S. Pichard, A. Imbard, J.F. Renoi, M.T. Abi Warde, et al., Neuropsychological profiles in MSUD school-age patients, J. Inherit. Metab. Dis. 40 (2017) 377–383.

[19] J.W. Lustbader, M.M. Grillii, C. Lin, H.W. Xu, K. Takuma, et al., ABAD directly links A to mitochondrial toxicity in Alzheimer's disease, Science 304 (2004) 448–452.

[20] K. Donnelly, The development of an instrument for assessing cognitive ability and screening for the cognitive decline associated with dementia in people with moderate to profound intellectual disability, PhD thesis (2015) Available at: https://eprints.qut.edu.au/83727/4/Karen_Donnelly_Thesis.pdf , Accessed date: 6 March 2018.

[21] L.-P. Lin, S.-W. Hsu, C.-L. Wu, C. Chu, J.-D. Lin, Association of early-onset dementia with activities of daily living (ADL) in middle-aged adults with intellectual disabilities: the caregiver's perspective, Res. Dev. Disab. 35 (3) (2014) 631–636.

[22] P. Wit, S. Elders, The 'Severe impairment Battery': assessing cognitive ability in adults with down syndrome, Brit. J. Clin. Psychol. 37 (1998) 213.

[23] J.W. Lustbader, M.M. Grillii, C. Lin, H.W. Xu, K. Takuma, et al., ADAR directly links A to mitochondrial toxicity in Alzheimer's disease, Science 304 (2004) 448–452.

[24] J.W. Lustbader, M.M. Grillii, C. Lin, H.W. Xu, K. Takuma, et al., ADAR directly links A to mitochondrial toxicity in Alzheimer's disease, Science 304 (2004) 448–452.

[25] P.L. Harrison, T. Oakland, Adaptive Behaviour Assessment System. Manual, 3th ed, Western Psychological Services, Torrance, CA, 2015.

[26] D. Wechsler, Technical and Interpretive Manual, Pearson, Texas: USA, 2008.

[27] D. Wechsler, Wechsler Intelligence Scale for Children, 3rd ed., NCS Pearson, Inc, Bloomington, MN, 2016.

[28] S.S. Sparrow, D.V. Cicchetti, C.A. Saulnier, Vineland Adaptive Behaviour Scales Manual, 3rd ed., NCS Pearson, Inc, Bloomington, MN, 2016.

[29] D. Wechsler, The development of an instrument for assessing cognitive ability and screening for the cognitive decline associated with dementia in people with moderate to profound intellectual disability, PhD thesis (2015) Available at: https://eprints.qut.edu.au/83727/4/Karen_Donnelly_Thesis.pdf , Accessed date: 6 March 2018.

[30] K.M. Stepien et al. Molecular Genetics and Metabolism Reports 16 (2018) 31–35

Acknowledgments

All authors would like to thank The Metabolic Laboratory at Temple Street Hospital for their ongoing support in monitoring biochemical parameters in patients with Inherited Metabolic Diseases.